COMUNICADO: "Am I Number 12?" (y 2)

Actualizado 19/05/2008 11:03:51 CET

For broadcast-standard video supporting this press release, please visit http://www.thenewsmarket.com/roche. If you are a first-time user, please take a moment to register. Questions may be directed to: journalisthelp@thenewsmarket.com. References: 1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.

2. World Health Organization. Initiative for Vaccine Research, Viral Cancers, Hepatitis C. 2006. (Accessed July 24, 2006, at http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.)

3. Eurasian Harm Reduction Network (EHRN). Comparative analysis of HCV prevalence across selected countries of Europe and the Mediterranean area; 1 October 2007.

4. AIDS Epidemic Update. 2006. (Accessed October 26, 2007, at http://www.who.int/hiv/mediacentre/2006_EpiUpdate_en.pdf.)

5. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.


For more information, please contact:

Mike Nelson, Roche,
International Communications Manager,
+41-795-72-5165;

Michelle Marchione,
Axon Communications,
+44(0)20-8439-9449.

For more information, please contact: Mike Nelson, Roche, International Communications Manager, +41-795-72-5165; Michelle Marchione, Axon Communications, 19 May. (0) - 20-8439-9449.

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación